This content is machine translated Ten years of living with Fukushima The nuclear disaster and cancer For 40 years, IPPNW, the group of International Physicians for the Prevention of Nuclear War, has been working for a world without nuclear threats. Ten years after the nuclear disaster…
View Post 3 min This content is machine translated Advanced malignant melanoma Adjuvant immunotherapy with nivolumab: promising long-term results According to current study data, more than half of the patients who received adjuvant treatment with the anti-PD-1 antibody were relapse-free after four years. This is further confirmation of the…
View Post 10 min This content is machine translated Side effect management Immune checkpoint inhibitor associated neurological side effects. Immune checkpoint inhibitors are finding increasingly widespread use in oncology with some breakthrough success. However, the activation of the immune system also triggers a wide range of side effects. Neurological… CME-Test
View Post 7 min This content is machine translated Urothelial carcinoma The role of checkpoint inhibitors Immunotherapy is also becoming increasingly important in the treatment of urothelial carcinoma. Checkpoint inhibitors are already being used successfully, particularly in advanced tumors. Now, potential applications of avelumab, atezolizumab and…
View Post 16 min This content is machine translated Actinic keratoses Prevention and Therapy – Guideline Recommendations and Future Developments The prevalence of current actinic keratosis (AK) sufferers in the population increases with age. Depending on UV exposure, the development of AK is relevant from the age of 40. In… CME-Test
View Post 2 min This content is machine translated Advanced high-grade serous ovarian cancer. HRD+ tumors: first PARP inhibitor approved for first-line maintenance therapy As the first and only PARP inhibitor, olaparib was recently approved by swissmedic for first-line maintenance therapy in patients with advanced, HRD-positive ovarian cancer. The addition of olaparib to bevacizumab resulted…
View Post 5 min This content is machine translated Prevention of non-melanocytic skin cancer (NMSC). Nicotinamide – blockbuster among cell-protective substances It is well known that UV radiation exposure is considered a major cause of non-melanocytic skin cancer by damaging DNA and inhibiting antitumor immunity. A reduction in intracellular ATP concentration,…
View Post 4 min This content is machine translated BRAFV600E-mutated metastatic colorectal cancer (mCRC). Evidence for additional benefit of dual blockade An expert panel finds considerable added benefit in the dual-blockade encorafenib combined with cetuximab in the treatment of metastatic colorectal cancer with BRAFV600E mutation after prior systemic therapy. This is…
View Post 5 min This content is machine translated Chronic lymphocytic leukemia BTK inhibitors and other hopefuls The therapy of chronic lymphocytic leukemia (CLL) is currently undergoing rapid change. Increasingly, chemoimmunotherapy, which has been commonly used in the past, is being replaced by more targeted treatments. In…
View Post 6 min This content is machine translated A reportage from life The doctor as patient Dealing with often serious illness is the most central element of the medical profession. Their own vulnerability is usually in the background. But what if it hits you? How does…
View Post 2 min This content is machine translated Non-small cell lung cancer with EGRF mutation. New approval for osimertinib for adjuvant therapy Following convincing results from the Phase III ADAURA study, the indication for osimertinib was expanded in Switzerland. Thus, the drug may now also be used for adjuvant therapy in early-stage…
